Comparative Validation of "Blinq" and "2WIN" Vision Screeners

Completed

Conditions studied: Strabismic Amblyopia, Refractive Amblyopia, Strabismus

In brief

After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending. Adult and children pediatric and strabismus patients were screened with blinq and "2WIN" photoscreener with "CR" corneal reflex alignment test and then compared to confirmatory exam with age-appropriate determination of binocular status.

Key facts

Study ID

NCT04195711

Run by

Alaska Blind Child Discovery

People needed

100

Starts

2019-11-18

Expected to finish

2019-11-26

Last updated by the study team

2020-10-19

Who can join

Age: 1 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Children in Pediatric Ophthalmology Practice Adult strabismus patients

You may not qualify if…

• patients with enucleations patients with eviscerations patients with exenterations

Where it is running

• Alaska Children's EYE & Strabismus — Anchorage, Alaska, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.